Skip to content
Aerami Therapeutics

Aerami Therapeutics

Reimagining the treatment of chronic diseases with Inhaled Therapies

  • ABOUT US
  • Inhalation Technology
  • Pipeline
  • INVESTORS + MEDIA
  • CONTACT
  • linkedin
  • twitter

Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China

February 9, 2021
Continue Reading

Aerami KOL Call: Inhaled Imatinib (AER-901) for the Treatment of Pulmonary Arterial Hypertension

August 18, 2020
Continue Reading

Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium

July 23, 2020
Continue Reading

Nurturing The Next Generation Of Top Talent

June 25, 2020
Continue Reading

Working Life – June 2020

June 25, 2020
Continue Reading

Durham-based startup targeting diabetes raises $4.6M, looks for another $10.4M

June 19, 2020
Continue Reading

Aerami Therapeutics Signs a Global License Agreement with Vectura Group, Adding an Inhaled Therapy for Patients with Pulmonary Arterial Hypertension to Their Pipeline

June 8, 2020
Continue Reading

Aerami Therapeutics Appoints Timm Crowder as Chief Operating Officer

February 5, 2020
Continue Reading

Dance Biopharm Partners With DarioHealth to Expand Access to Digital Therapeutics Platform for Patients With Chronic Diseases

September 11, 2019
Continue Reading

Dance Biopharm to Present Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting

June 4, 2019
Continue Reading

Categories

  • In The News
  • PRESS RELEASES

Archives

  • 2021
  • 2020
  • 2019
  • 2017

Investor Contact:

Steve Thornton
Aerami Therapeutics, Inc.
(919) 589-8862
sthornton@aerami.com

Media Contact:

Chad Whitaker
Aerami Therapeutics, Inc.
(919) 355-5864
cwhitaker@aerami.com

  • linkedin
  • twitter

2520 Meridian Parkway, Suite 400
Durham, North Carolina 27713
info@aerami.com

© 2020 Aerami Therapeutics.
All Rights Reserved.  Privacy Policy